Navigation Links
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Date:2/14/2008

y will streamline operations by reducing its work force. In addition, Neil Kurtz, M.D., the company's President and Chief Executive Officer, will assume oversight of all clinical development programs. Michael Murphy, who has served as Chief Medical Officer, will leave the company at the end of the month to pursue other interests.

"Our 2008 strategic plan builds on the clinical successes of our lead compounds and our on-going genetics collaboration with Eisai while enabling us to be opportunistic and fiscally prudent," said Dr. Kurtz. "Our goal is to exploit the versatility of our product candidates by moving them forward strategically through at least proof-of-concept, while being aggressive in our pursuit of corporate partnerships."

Conference Call/Webcast Information

TorreyPines Therapeutics will host a conference call and Webcast at 11 a.m. EST today. The audio Webcast can be accessed at http://www.torreypinestherapeutics.com. To participate in this call, dial 785-830-7975 and enter the passcode 1575547. For a limited period following the call, a replay will be available beginning at 2 p.m. EST. The replay can be accessed by calling 719-457-0820 and entering passcode 1575547.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small molecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com

This press release contains forward-looking statements or predictions, including statements regarding the company's
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
5. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
8. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
9. ImaRx Therapeutics Transitions Business Strategy
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... cameraman who was diagnosed with Ebola while working for NBC ... and can leave the special isolation unit at Nebraska Medical Center ... weeks, the hospital said Tuesday. A blood test confirmed by ... Mukpo, 33, can head home to Providence, R.I., NBC News ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... World Health Organisation (WHO) has said that the risk of ... In a report analyzing 205 infections that occurred from December ... have peaked in winter and spring months, the WHO also ... this year or early next year. "If this pattern continues, ...
... World Food Programme (WFP) announced on Wednesday that as ... acute food shortage in Southern Africa. //WFP executive director ... recent years, there was a distribution problem. ... to eat," he said. "Food and good nutrition are ...
... Noel Colina, the executive director at the Institute for Occupation ... night shifts are more prone //to develop breast cancer. Citing ... said that a number of women were taking up work ... 6 a.m. ,This type of work usually done ...
... A protein that allows breast cancer cells to evade the body’s ... according to a study by Keck School of Medicine of USC ... issue of the American Journal of Pathology, is the first to ... of cells – functions. ,“The important aspect of ...
... Glucosamine, a substance used in treating arthritis was now found ... UV damaged skin and preventing the //formation of new age ... Harvard Medical School have reported that the more stable n-acetyl ... cells thus proved its effect in UV-related skin damage treatment. ...
... Shire was the foremost patch medication approved to treat ... of methylphenidate - DAYTRANA, is now available in pharmacies ... 20 mg and 30 mg. ,'The availability of DAYTRANA, ... and parents with a new, practical way to individualize ...
Cached Medicine News:Health News:Researchers Investigate Protein that Protects Tumors 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 2Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 4
McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: